Compounders Research Compare

Greenwich LifeSciences, Inc.(GLSI)

Biotechnology · Stafford, TX

$16.54-0.37 (-2.18%)

Delayed quote: Oct 6, 2026, 1:07 PM EDT

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stafford, TX

13 employees

greenwichlifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Snehal S. Patel

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T17:12:45.860Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:12:45.860Z.

Quote observation: 2026-10-06T17:07:49.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 242,798,110
TTM free cash flow · period ending 2026-06-30: -12,488,143

FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GLSI Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

GLSI Competitors' Price/FCF Ratio

Greenwich LifeSciences, Inc.

Current

Market Cap

$242.80M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lifecore Biomedical, Inc.

Market Cap

$242.50M

Price/FCF Ratio

N/A

TTM Avg

780.39

3Y Avg

474.08

5Y Avg

244.04

Q32 Bio Inc.

Market Cap

$242.28M

Price/FCF Ratio

N/A

TTM Avg

8.17

3Y Avg

8.17

5Y Avg

8.17

Quantum-Si incorporated

Market Cap

$246.31M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nautilus Biotechnolgy, Inc.

Market Cap

$241.78M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Galectin Therapeutics Inc.

Market Cap

$241.04M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CAMP4 Therapeutics Corporation

Market Cap

$239.72M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InflaRx N.V.

Market Cap

$237.23M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Century Therapeutics, Inc.

Market Cap

$248.98M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Sol-Gel Technologies Ltd.

Market Cap

$249.91M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Greenwich LifeSciences, Inc. (GLSI)	$242.80M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$242.50M	N/A	780.39	474.08	244.04
Q32 Bio Inc. (QTTB)vs ›	$242.28M	N/A	8.17	8.17	8.17
Quantum-Si incorporated (QSI)vs ›	$246.31M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$241.78M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$241.04M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$239.72M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$237.23M	N/A	N/A	N/A	N/A
Century Therapeutics, Inc. (IPSC)vs ›	$248.98M	N/A	N/A	N/A	N/A
Sol-Gel Technologies Ltd. (SLGL)vs ›	$249.91M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics